Shareholders to Vote on SPAC Extension to Pursue Power Analytics Global Merger

summarizeSummary

Drugs Made In America Acquisition Corp. filed a definitive proxy statement for an extraordinary general meeting on April 27, 2026, seeking shareholder approval to extend its business combination deadline to April 29, 2027, to facilitate its recently announced non-binding Letter of Intent with Power Analytics Global Corp.

check_boxKey Events

• Extraordinary General Meeting Scheduled

  An Extraordinary General Meeting will be held on April 27, 2026, for shareholders to vote on critical proposals regarding the company's future.

• Extension Proposal to Avoid Liquidation

  Shareholders will vote on amending the company's charter to extend the business combination deadline from April 29, 2026, to April 29, 2027. This extension is necessary to avoid liquidation and allow time to complete a potential merger.

• Facilitates Power Analytics Global Corp. LOI

  The proposed extension is directly linked to the non-binding Letter of Intent to merge with Power Analytics Global Corp., which was announced on April 8, 2026. The board believes more time is needed to finalize this transaction.

• Public Shareholder Redemption Rights

  Public shareholders can redeem their shares for approximately $10.52 per share if the Extension Proposal is approved, offering an exit at or near the current market price.

auto_awesomeAnalysis

Drugs Made In America Acquisition Corp. has filed a definitive proxy statement for an extraordinary general meeting on April 27, 2026, seeking shareholder approval to extend its deadline for completing a business combination. This extension, from April 29, 2026, to April 29, 2027, is crucial for the company to finalize its recently announced non-binding Letter of Intent (LOI) to merge with Power Analytics Global Corp. Without this extension, the SPAC would be forced to liquidate, returning funds to shareholders but ending the potential merger. Public shareholders have the option to redeem their shares for approximately $10.52 per share, which is near the current market price, providing a protective exit. The sponsor has committed to funding the monthly extensions, demonstrating continued support for the proposed transaction.